AbbVie Inc. (ABBV)
Healthcare Rotation Underway: 3 Stocks Leading the Charge
Is the artificial intelligence revolution hitting its first roadblock? For the first time since the AI boom began in 2023, the industry is starting to feel the weight of expectations, and many of the tech sector's biggest winners have been struggling amidst a volatile market.
Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3
ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.
It's Best Time In 10 Years To Lock In Income: Our Picks
Investors can now access 4–7% from top-quality REITs, 3.5%+ from dividend ETFs, and 6%+ from midstream infrastructure — without taking on excessive risk. While the S&P 500 is up ~110% since 2020, 70–80% of returns come from the Mag7, leaving broad-market returns near inflation levels. US inflation sits at 3%, and Western Europe reports 3.5–4%, emphasizing the need for income-producing assets to preserve purchasing power for retirees.
AbbVie Inc. (ABBV) Presents at 7th Annual Healthcare Symposium Transcript
AbbVie Inc. ( ABBV ) 7th Annual Healthcare Symposium November 14, 2025 11:55 AM EST Company Participants Michael Paas Conference Call Participants Elena Meng Michelle Kehily Stephen Morse Magdalena Sobieszczyk Presentation Operator Okay, everyone, if we can wrap up our conversations so that we can get started and come to the main room. So our final panel today is about vaccines.
Here Are Thursday's Top Wall Street Analyst Research Calls: AbbVie, AppLovin, Autozone, Booking Holdings, CoreWeave, DoorDash, and More
The stock futures are trading lower on Thursday, following another incredible day for the Dow Jones Industrials, while the rotation out of the NASDAQ and into technology is still gaining traction.
AbbVie Has Many Bullish Attributes (Technical Analysis)
AbbVie presents a bullish outlook supported by positive earnings, a strong dividend, and robust technical indicators. ABBV beat Q3 earnings and revenue expectations, raised full-year EPS guidance, and boasts a promising drug pipeline with strong Skyrizi and Rinvoq sales. Technically, ABBV trades above its 30-week EMA, shows bullish momentum, increasing institutional volume, and has outperformed the S&P 500 this year.
Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer
AbbVie's and Pfizer's Q3 earnings and dividend updates prompt a rating upgrade to Hold for ABBV and reiteration of Sell for PFE. PFE's higher yield (almost 7%) and single-digit P/E (FY1 P/E is ~8x only) can be attractive for deep value investors. The high yield and cheap valuation are for good reasons.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
ABBV Stock: $250 May Be the New Floor After Big Q3 Earnings Beat
AbbVie Inc. NYSE: ABBV delivered a strong third-quarter earnings report with a beat on the top and bottom lines and an increase in its forward guidance. The results clear the way for ABBV stock to make $250 the new floor for the stock.
Why AbbVie Stock Flopped on Friday
Despite the pharmaceutical giant's beat-and-raise third quarter, investors were expecting better. Profitability guidance, even though it was raised, came in under analyst estimates.
AbbVie Inc. (ABBV) Q3 2025 Earnings Call Transcript
AbbVie Inc. ( ABBV ) Q3 2025 Earnings Call October 31, 2025 9:00 AM EDT Company Participants Elizabeth Shea - Senior Vice President of Investor Relations Robert Michael - CEO & Chairman of the Board Jeffrey Stewart - Executive VP & Chief Commercial Officer Roopal Thakkar - Executive VP of Research and Development & Chief Scientific Officer Scott Reents - Executive VP & CFO Conference Call Participants Terence Flynn - Morgan Stanley, Research Division Christopher Schott - JPMorgan Chase & Co, Research Division Vamil Divan - Guggenheim Securities, LLC, Research Division Matthew Phipps - William Blair & Company L.L.C., Research Division David Amsellem - Piper Sandler & Co., Research Division David Risinger - Leerink Partners LLC, Research Division Steve Scala - TD Cowen, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Luisa Hector - Joh.
AbbVie Q3 Earnings & Sales Beat, 2025 EPS Outlook Raised
ABBV tops Q3 earnings and revenue estimates, driven by Rinvoq and Skyrizi gains, and lifts its 2025 EPS outlook.
